The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...
The Healthy on MSN8h
Nearly 7,000 Bottles of a Heart and Diabetes Medication Recalled in At Least One StateHowever, a recent recall affecting 6,804 bottles of metformin means some of the 20 million Americans on metformin will want ...
A popular diabetes drug just got a major new approval — and it could be a game-changer for millions of Americans at risk for kidney failure.
Observational data fill a knowledge gap in the absence of randomized trials comparing empagliflozin vs dapagliflozin in patients with type 2 diabetes.
Study led by Mount Sinai researcher shows sotagliflozin is the only drug in its class to demonstrate these results ...
Travere’s stock price climbed by 14% following the announcement that it will seek an FDA label expansion for Filspari.
Current mortality prediction models for patients with kidney failure may introduce bias and applicability concerns in clinical practice, according to a large systematic review. “Risk prediction models ...
A well-known class of drugs used to manage type 2 diabetes and control weight could offer hope for patients who also struggle ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback